Filtered By:
Source: Mass Device
Drug: Baclofen
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
Medtronic touts therapy delivered via SynchroMed pump in patients with post-stroke spasticity
Medtronic (NYSE:MDT) touted data today showing that intrathecal baclofen therapy delivered via the company’s SychroMed II infusion pump performed better than the conventional treatment for patients with severe post-stroke spasticity.
The medtech titan’s SynchroMed II pump is the only device approved in the U.S. for ITB therapy.
Get the full story at our sister site, Drug Delivery Business News.
The post Medtronic touts therapy delivered via SynchroMed pump in patients with post-stroke spasticity appeared first on MassDevice.
Source: Mass Device - January 11, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Neurological Pharmaceuticals Wall Street Beat Medtronic Source Type: news
